InvestorsHub Logo
Followers 1
Posts 261
Boards Moderated 0
Alias Born 09/11/2017

Re: None

Tuesday, 02/11/2020 5:54:02 PM

Tuesday, February 11, 2020 5:54:02 PM

Post# of 9943
https://filecache.investorroom.com/mr5ircnw_inmedpharma/278/InMed%20Corporate%20Slides%20-%20FINAL%202020-02-11.pdf

Shareholders should expect a detailed explanation of why they chose the alternative process for biosynthesis. If the biological burden in path #1 was not overcome and they are pivoting to an alternative process for the program at minimum this means more delays to commercialization.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INM News